Acceptance period for cash offer of €39 per QIAGEN share runs from May 18, 2020, to July 27, 2020

Acceptance period for cash offer of €39 per QIAGEN share runs from May 18, 2020, to July 27, 2020

First-of-its-kind commercial solution analyzes 3D and sub-surface data 15,000 times faster than a typical Ga-FIB

Collaboration with WuXi Diagnostics and Mayo Clinic on serology test will complement Thermo Fisher's widely adopted TaqPath COVID-19 molecular diagnostic test

Authorization brings more instruments on line, enables workflow flexibility and simplifies methods to increase throughput and allow more labs to run tests

New Plainville, Massachusetts, site will accelerate commercialization of cell and gene therapies

Company to provide 50 Ion Torrent Genexus Systems for consortia members at a subsidized price to support global COVID-19 research

New Ion AmpliSeq SARS-CoV-2 Research Panel, now optimized for the Ion Torrent Genexus System*, assists with contact tracing to identify coronavirus hot spots

New FDA-cleared Microbroth Dilution Susceptibility Plates offer immediate testing options to microbiology laboratories providing the most up-to-date therapy for critically ill patients